Treatment Of Lung Cancer Using A Combination Of An Anti-Pd-1 Antibody And An Anti-Ctla-4 Antibody
Patent No. EP3377534 (titled "Treatment Of Lung Cancer Using A Combination Of An Anti-Pd-1 Antibody And An Anti-Ctla-4 Antibody") was filed by Bristol Myers Squibb on Nov 18, 2016. The application was issued on Jun 18, 2025.
Patent Summary
Combination therapy for non-small cell lung cancer (NSCLC) comprising an anti-PD-1 antibody (e.g. nivolumab) and an anti-CTLA-4 antibody (e.g. ipilimumab) administered at specific dosing regimens, wherein at least 50% of tumor cells express PD-L1. The therapy is effective in increasing progression-free survival and overall survival in NSCLC patients, including those with squamous and non-squamous histologies.
Patent Family
Patent Oppositions (3)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3377534
- Application Number
- EP16819718A
- Filing Date
- Nov 18, 2016
- Status
- Granted And Under Opposition
- May 16, 2025
- Publication Date
- Jun 18, 2025
- External Links
- Slate, Register , Google Patents